Literature DB >> 18361890

[Organizing pneumonia associated with the use of pegylated interferon alfa].

Joan-Carles Trullas Vila1, Demetrio-Roberto Padilla López, Vicenta Bisbe Company, Silvia Soler Simón, Pere Cortés Hausmann, Josep Bisbe Company.   

Abstract

Organizing pneumonia is a well-differentiated clinical and histologic entity whose onset is usually subacute with respiratory symptoms and pulmonary infiltrates. Its origin may be unknown (cryptogenic) or it may be associated with various medical conditions, infectious diseases, or drugs. Diagnosis is confirmed by the presence of foci of organizing pneumonia in lung biopsy specimens. Our patient was a 49-year-old man infected with the hepatitis C virus who was receiving pegylated interferon alfa-2b. He presented with dry cough, fever, dyspnea, and ground glass pulmonary infiltrates. After an open lung biopsy, he was diagnosed with organizing pneumonia. When pegylated interferon was discontinued and corticosteroids started, the symptoms and pulmonary infiltrates disappeared. To our knowledge, this is the second report of organizing pneumonia related to pegylated interferon alfa-2b.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18361890

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  3 in total

1.  Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population.

Authors:  Lis R V Antonelli; Antonio Gigliotti Rothfuchs; Ricardo Gonçalves; Ester Roffê; Allen W Cheever; Andre Bafica; Andres M Salazar; Carl G Feng; Alan Sher
Journal:  J Clin Invest       Date:  2010-04-12       Impact factor: 14.808

2.  Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers.

Authors:  Priya Muralidharan; Evan Mallory; Monica Malapit; Don Hayes; Heidi M Mansour
Journal:  Pharmaceutics       Date:  2014-06-20       Impact factor: 6.321

3.  Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy.

Authors:  Amit Chopra; Creticus Marak; Narendrakumar Alappan; Chang Shim
Journal:  Case Rep Pulmonol       Date:  2015-01-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.